NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/18/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,661.24 mln
Float205 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.7
Highly suspicious
1-Year Forecast
10.43
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.15
Very low leverage
ROE
-14.69
Negative
Business Description
Founded in 2012 and based in Vancouver, Canada, AbCellera Biologics works to find and build new antibody treatments for patients who currently have few good options. The company has two drugs moving through clinical trials: one non-hormonal treatment for hot flashes and night sweats, and another targeting certain immune system disorders like atopic dermatitis. AbCellera works alongside major partners including Eli Lilly, AbbVie, and Biogen to advance its research and bring new medicines to market.
